MedPath

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

Not Applicable
Active, not recruiting
Conditions
Smoking Cessation
Interventions
Behavioral: Removal of Financial Barriers
Behavioral: Financial Incentives
Behavioral: Mobile Health Application
Registration Number
NCT04798664
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Brief Summary

To compare the effectiveness of four interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer screening at four large U.S. health systems.

Detailed Description

We will conduct a 4-arm randomized trial comparing 4 interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among smokers in underserved demographic groups. The 3,200 participants to be enrolled will be current smokers who are Black, Hispanic, and/or have low socioeconomic status (defined as household income \<200% of the federal poverty line or a high school education or less) or rural residence who are referred for low-dose computed tomography (LDCT) screening at 4 large health systems. All adult patients with LDCT orders will be further screened for eligibility. Eligible patients will enroll with opt-out consent and complete the study using the NIH-funded Way to Health online research portal. The primary outcome will be biochemically confirmed, sustained abstinence from smoking tobacco for 6 months following participants' selected quit dates. Relapse rates will be tracked at 12 months.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
3228
Inclusion Criteria
  • Current smoker (≥ 1 cigarettes per day, not including e-cigarettes)
  • Has a low-dose computed tomography (LDCT) scan ordered by their physician
  • Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c) rural residence, or (d) low socioeconomic status (Defined as one or both of: high-school education or less, or household income <200% of the federal poverty line)
  • Able to receive study invitation and screening, by virtue of showing up to a radiology location affiliated with a participating health system for the LDCT, or having a valid email address or telephone number on file with the health system
  • Access to a cell phone with text messaging or the internet
  • Aged 18 years or older
Exclusion Criteria
  • No cell phone

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Enhanced Usual Care plus Financial Incentives plus Mobile Health ApplicationRemoval of Financial BarriersParticipants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.
Enhanced Usual Care plus Financial Incentives plus Mobile Health ApplicationFinancial IncentivesParticipants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.
Enhanced Usual Care plus Financial Incentives plus Mobile Health ApplicationMobile Health ApplicationParticipants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.
Enhanced Usual CareRemoval of Financial BarriersParticipants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
Enhanced Usual Care plus Financial IncentivesRemoval of Financial BarriersParticipants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
Enhanced Usual Care plus Financial IncentivesFinancial IncentivesParticipants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
Primary Outcome Measures
NameTimeMethod
Biochemically confirmed smoking abstinence sustained for 6 months6 months

The primary outcome measure is sustained abstinence for 6 months, and will require self-report of smoking cessation followed by biochemical confirmation at 2 weeks, 3, and 6 months.

Secondary Outcome Measures
NameTimeMethod
Quit status (self-report)2 weeks, 3 months, 6 months, 12 months

Point-prevalent rates of self-reported nicotine use and tobacco product use

Quit status (biochemically confirmed)2 weeks, 3 months, 6 months,12 months

Point-prevalent rates of biochemically confirmed smoking cessation

Health-related quality of lifeBaseline, 6 months, 12 months

The EuroQuol Group's quality of life (EQ-5D) scale is a 25-item validated scale used to assess patients' perceived health-related quality of life across the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

Perceived barriers to cessationBaseline, 6 months, 12 months

The Challenges to Stopping Smoking Scale (CSS-21) is a validated 21-item measure to assess patients' perceived barriers to smoking cessation. The CSS-21 has two sub-scales: intrinsic factors (physical, psychological or cognitive aspects of quitting) and extrinsic factors (social or environmental aspects of quitting).

Temporal ("delay") discountingBaseline, 6 months, 12 months

Temporal discounting is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. We will use the 5-Trial Adjusting Delay Task to assess temporal discounting.

Self-efficacy related to cessation effortsBaseline, 6 months, 12 months

We will use the 10-item situational measure of self-efficacy related to smoking behavior. This scale measures how sure participants are that they can avoid smoking in different situations.

Motivation to quitBaseline, 6 months, 12 months

The Stages of Change (SOC) is a validated 1-item measure to assess patient's self-reported motivation to quit.

Trial Locations

Locations (5)

Lancaster General Health

🇺🇸

Lancaster, Pennsylvania, United States

Kaiser Permanente Southern California

🇺🇸

Oakland, California, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Geisinger

🇺🇸

Danville, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath